

DAFTAR PUSTAKA

1. Jang JG, Chung JH. Diagnosis and treatment of multidrug-resistant tuberculosis. 2020; 37(4):277–85.
2. World Health Organization. Global Tuberculosis Report 2024. Geneva: World Health Organization; 2024: p1-50.
3. Kementrian Kesehatan RI. Profil Kesehatan Indonesia 2023. Jakarta: Kementerian Kesehatan Republik Indonesia; 2024: h149–54.
4. Direktorat Jenderal Pencegahan dan Pengendalian Penyakit (P2P). Petunjuk Teknis Penatalaksanaan Tuberkulosis Resistan Obat di Indonesia. Jakarta: Kementerian Kesehatan Republik Indonesia; 2024: h1-49.
5. Dinas Kesehatan Kota Padang. Profil Kesehatan Kota Padang Tahun 2022. Padang: Dinas Kesehatan; 2020. h68-72.
6. Aminah NS, Djuwita R. Trend dan Faktor yang Berhubungan dengan Keberhasilan Pengobatan Pasien TB RO Paduan Jangka Pendek di Indonesia 2017-2019. Pro Heal J Ilm Kesehat. 2021; 3(1): 109–17.
7. Aviana F, Jati SP, Budiyan RT. Systematic Review Pelaksanaan Programmatic Management Of Drugresistant Tuberculosis Pada Pasien Tuberkulosis Resistan Obat. J Kesehat Masy. 2021; 9(2): 215–22.
8. Deviernur SM, Adnan N. Analisis Survival : Hubungan Konversi Sputum dengan Keberhasilan Pengobatan Pasien Tuberkulosis Resistan Obat di Indonesia Analisis Survival : Hubungan Konversi Sputum dengan Keberhasilan Pengobatan Pasien Tuberkulosis Resistan Obat di Indonesia. J Epidemiol Kesehat Indones. 2023; 7(1): 43–50.
9. Indrasari AD, Fathana PB. Studi literatur: pathogenesis dan diagnosis tuberkulosis resisten obat. Jurnal Medika Malahayati. 2024; 8(1): 162-70.
10. Liebenberg D, Gordhan BG and Kana BD. Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management. Front. Cell. Infect. Microbiol. 2022; 12:943545.

11. Putri O, Salim MA, Gunawan A, Devin, Amaris E, Alexander D, et al. Drug-Resistant Pulmonary Tuberculosis: Current Standings in Indonesia. *Indonesian Journal of Life Sciences*. 2023; 5(1): 10-41.
12. WHO operational handbook on tuberculosis. Module 4: Drug-resistant tuberculosis treatment 2022 update. Geneva: World Health Organization; 2022: p1-56.
13. Perhimpunan Dokter Paru Indonesia. Tuberkulosis: Pedoman Diagnosis dan Penatalaksanaan di Indonesia. Jakarta: PDPI; 2021: h1-58.
14. Wenlu Y, Xia Z, Chuntao W, Qiaolin Y, Xujue X, Rong Y, et al. Time to sputum culture conversion and its associated faktors among drug-resistant tuberculosis patients: a systematic review and meta-analysis. *BMC Infect Dis*. 2024; 24(1): 169-75.
15. Salari N, Kanjoori AH, Hosseinian-Far A, Hasheminezhad R, Mansouri K, Mohammadi M. Global prevalence of drug-resistant tuberculosis: a systematic review and meta-analysis. *Infect Dis Poverty*. 2023; 12(1): 57-68.
16. Dwiastuti I, Musdalifah A, Masriadi M, Junus A, Asdar M. Estimasi Kasus TB Paru Resisten Obat di Provinsi Sulawesi Selatan (Pemodelan Sistem Dinamis). Ghidza: Jurnal Gizi Dan Kesehatan. 2021; 5(2): 133-9.
17. Ramadhani AR, Lestari BW, Suryadinata H. Knowledge toward Drugs Resistant Tuberculosis in One of the Highest Burden Drug Resistant Country. *AMJ*. 2018; 5(3):127–32
18. Annisatuzzakiyah I, Bahar E, Biomechy OP. Gambaran Riwayat Pengobatan Tuberkulosis Pada Pasien Multi Drug Resistant Tuberculosis di RSUP Dr. M. Djamil Padang Tahun 2018-2019. *Jurnal Ilmu Kesehatan Indonesia*. 2021; 2(1):
19. Dinas Kesehatan Pemerintah Kota Solok. Profil Kesehatan Kota Solok. Solok: Dinas Kesehatan Kota Solok; 2022: h1-170.
20. Chasanah KF, Trinawati I, Istiono W. Risk faktor identification of multi-drug resistant tuberculosis in Special Region of Yogyakarta. *Rev Prim Care Prac and Educ*. 2022; 5(1): 20-4.

21. Artha D. Gambaran Resistensi Bakteri Terhadap Obat Rifampisin Pada Pasien Penderita Tuberkulosis di RSUP Dr. M. Djamil Padang. *Jurnal Ilmu Kesehatan Indonesia*. 2020; 5(2): 1-14.
22. Abraham AO, Nasiru AU, Abdulazeez AK, Seun OO, Ogonna DW. Mechanism of Drug Resistance in Mycobacterium Tuberculosis. *Am J Biomed Sci & Res*. 2020. 1-19.
23. Nimmo C, Millard J, Faulkner V, Monteserin J, Pugh H and Johnson E. Evolution Mycobacterium tuberculosis drug resistance in the genomic era. *Front. Cell. Infect. Microbiol*. 2022; 12:954074.
24. Pedoman Nasional Pelayanan Kedokteran. Tatalaksana Tuberkulosis. Jakarta: Kementrian Kesehatan RI; 2020: h1-53.
25. Su WJ, Feng JY, Chiu YC, Huang SF, Lee YC. Role of 2-month sputum smears in predicting culture conversion in pulmonary tuberculosis. *Eur Respir J*. 2021;37(2):376-83.
26. Rodriguez CA, Brooks MB, Aibana O, Mitnick CD, Franke MF. Sputum culture conversion definitions and analytic practices for multidrug-resistant TB. *Int J Tuberc Lung Dis*. 2021; 25(7):591–8.
27. Khor LA, Wahid UNI, Ling LL, Liansim SMS, Oon J, Balakrishnan MN, et al. Prevalence and associated factors of delayed sputum smear conversion in patients treated for smear positive pulmonary tuberculosis: A retrospective follow up study in Sabah, Malaysia. *PLoS ONE*. 2023; 18(3): e0282733.
28. Adolphus C, Lydia N, Kalyango J, Katamba A, Mupere E, Emmanuel S, et al. Incidence and Factors Associated with Late Sputum Culture Conversion Among Multi- Drug-Resistant Tuberculosis Patients on Treatment in National Referral Hospital Uganda. *medRxiv*. 2024: 230-6.
29. Liu Q, Lu P, Martinez L, Yang H, Lu W, Ding X. *et al*. Factors affecting time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis in China. *BMC Infect Dis*. 2018; 18 (1): 114-28.
30. Mahendrani M, Subkhan M, Nurida A, Prahasanti K, Levani Y. Analisis faktor yang berpengaruh terhadap konversi sputum basil tahan asam pada penderita

- tuberkulosis. *AL-IQRA Med J.* 2020;3(1):1–9.
31. Agazhe M, Alene M, Petrucka P, Tesema C, Bekele D. International Journal of Infectious Diseases Time to sputum culture conversion and its associated faktors among multidrug-resistant tuberculosis patients in Eastern Africa : A systematic review and meta-analysis. *Int J Infect Dis.* 2020;98:230–6.
 32. Gamachu M, Deressa A, Birhanu A, Ayana GM, Raru TB, Negash B, et al. Sputum smear conversion and treatment outcomes among drug-resistant pulmonary tuberculosis patients in eastern Ethiopia: A 9-years data analysis. *Front. Med.* 2022; 9:1007757.
 33. Ernawati K, Ramdhagama NR, Ayu LAP, Wilianto M, Dwianti VTH. Perbedaan Status Gizi Penderita Tuberkulosis Paru antara Sebelum Pengobatan dan Saat Pengobatan Fase Lanjutan di Johar Baru , Jakarta Pusat Differences in Nutritional Status of Pulmonary Tuberculosis Patients between Before Medication and during Advanced. *Bandung Med J.* 2018;50(2): 1-14
 34. Mulugeta Gamachu, Alemayehu Deressa, Lemma Demissei Regassa, Miesso Bayu, Ibsa Mussa, Fekede Asefa Kumsa, Tariku Dingeta, Sputum culture conversion and its predictors among drug-resistant pulmonary tuberculosis patients in eastern Ethiopia, *International Health.* 2024; 32(1): 1-15.
 35. Weldemhret L, Atsbaha AH, Bekuretsion H, Desta A, Legesse L, Kahsay G, et al. Time to Sputum Culture Conversion and Its Predictors Among Multidrug Resistant Tuberculosis Patients in Tigray, Northern Ethiopia: Retrospective Cohort Study. *Infect Drug Resist.* 2023; 16(1): 3671-81.
 36. Abubakar M, Ahmad N, Atif M. Prognostic accuracy of time to sputum culture conversion in predicting cure in extensively drug-resistant tuberculosis patients: a multicentre retrospective observational study. *BMC Infect Dis.* 2022;22(1):204-12.
 37. Soeroto AY, Pratiwi C, Santoso P, Lestari BW. Faktors affecting outcome of longer regimen multidrug-resistant tuberculosis treatment in West Java Indonesia: A retrospective cohort study. *PLoS ONE.* 2021; 16(2): e0246284

38. Javaid A, Ahmad N, Afridi AK, Basit A, Khan AH, Ahmad I, et al. Validity of Time to Sputum Culture Conversion to Predict Cure in Patients with Multidrug-Resistant Tuberculosis: A Retrospective Single-Center Study. *Am J Trop Med Hyg.* 2018;98(6):1629-36.
39. Ahmad R, Patel S, Kumar N. *Adverse Drug Reactions and Treatment Discontinuation in Patients with Drug-Resistant Tuberculosis: A Retrospective Study.* Journal of Tuberculosis Research. 2022; 10(3): 125-35.
40. Gupta V, Sharma P, Singh A. *Linezolid-Induced Neuropathy and Treatment Outcomes in Drug-Resistant Tuberculosis Patients: A Cohort Study.* International Journal of Infectious Diseases. 2021; 95(4): 210-18.
41. Wardani DWSR, Pramesona BA, Septiana T, Soemarwoto RAS. Risk faktors for delayed sputum conversion: A qualitative case study from the person-in-charge of TB program's perspectives. *J Public Health Res.* 2023; 12(4): 22799036231208355.
42. Ambarsari U, Arimbi MR, Veterini L, Indrianto YL, Candini NA, Notobroto HB. Synchronization of Sputum Conversion and Resolution of Intensive Phase Lesion Areas on Thorax X-rays Determinants of Prognosis for Pulmonary Tuberculosis Therapy. *Medical And Health Science Journal.* 2023; 7(2): 1-17.
43. Alzarea AI, Alanazi AS, Saifullah A, Alatawi AD, Khan YH, Algarni MA, et al. Evaluation of time to sputum smear conversion and its association with treatment outcomes among drug-resistant tuberculosis patients: a retrospective record-reviewing study. *Front Pharmacol.* 2024;15 :1370344.
44. Madaki S, Mohammed Y, Rogo LD, Yusuf M, Bala YG. Age and gender in drug resistance tuberculosis: A cross-sectional case study at a national tuberculosis reference hospital in Nigeria. *Clin Epidemiol Glob Health.* 2024;29 :101445
45. Burhan E, Karyana M, Karuniawati A, Kusmiati T, Wibisono BH, Handayani D, et al. Characteristics of Drug-sensitive and Drug-resistant Tuberculosis Cases among Adults at Tuberculosis Referral Hospitals in Indonesia. *Am J Trop Med Hyg.* 2022; 107(5): 984–91

46. Dash M, Behera BP. Socioepidemiological status and clinical outcome of MDR TB patients in a tertiary medical college in Southern Odisha. *J Family Med Prim Care*. 2022;11(4):1275–81.
47. Pasha I, Ashraf A. Clinical characteristics and outcome predictors in drug-resistant tuberculosis: A comprehensive analysis. *Adv Res*. 2024; 25(5): 67-79.
48. Kurnianingsih W, Tamtomo DG, Murti B. The Effect of Non-Compliance with Medication on Multidrug Resistant of Tuberculosis. *Journal of Epidemiology and Public Health*. 2020; 05(04): 442-50
49. Niki M, Yoshiyama T, Nagai H, Miyamoto Y, Niki M, Oinuma Ki, et al. Nutritional status positively impacts humoral immunity against its Mycobacterium tuberculosis, disease progression, and vaccine development. *PLoS ONE*. 2020; 15(8): e0237062.
50. Ratnasari NY. Faktor risiko kejadian multidrug resistant tuberculosis (MDR TB) di Surakarta, Jawa Tengah. *Jurnal Penelitian Kesehatan Suara Forikes*. 2020; 11: 67-72.
51. Makabayi MR, Musaazi J, Zawedde MS, Kizito E, Fatta K, Namwanje KH, et al. Community-based directly observed therapy is effective and results in better treatment outcomes for patients with multi-drug resistant tuberculosis in Uganda. *BMC Health Serv Res*. 2023;23(1):1248.
52. Herman D, Machmud R, Lipoeto NI. Unraveling the link between obesity and tuberculosis: a systematic review of the underlying mechanisms. *Bioscientia Medicina*. 2024; 9(2): 6453–66.
53. Soedarsono S, Mertaniasih NM, Kusmiati T, Permatasari A, Ilahi WK, Anggraeni AT. Characteristics of Previous Tuberculosis Treatment History in Patients with Treatment Failure and the Impact on Acquired Drug-Resistant Tuberculosis. *Antibiotics*. 2023; 12: 598-607.
54. Kebede AH, Mamo H. Multidrug-resistant tuberculosis treatment outcomes and associated factors at Yirgalem General Hospital, Sidama Region, South Ethiopia: a retrospective cohort study. *BMC Pulm Med*. 2024; 24: 527.

55. Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of highly drug-resistant pulmonary tuberculosis. *N Engl J Med*. 2020; 382(10): 893–902.
56. Liu Q, Lu P, Martinez L, Yang H, Lu W, Ding X. *et al*. Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China. *Eur Respir J*. 2017; 49(3):1601558.
57. Hosu MC, Faye LM, Apalata T. Dynamics of Sputum Conversion in Drug-Resistant Tuberculosis: A Retrospective Study in Rural Eastern Cape. *Preprints*. 2025: 2025030831.
58. Asemahagn MA. Sputum smear conversion and associated factors among smear-positive pulmonary tuberculosis patients in East Gojjam Zone, Northwest Ethiopia: a longitudinal study. *BMC Pulm Med*. 2021; 21(1):118-28.
59. Nofal IMM, AbdelHalim HA, Almaraghy AA, Awad AM, Farrag MA. Characteristics and treatment outcomes of patients with multi-drug-resistant tuberculosis at Abbassia Chest Hospital. *Egypt J Bronchol*. 2024; 18: 97
60. Santy D, Siagian P, Sinaga BYM, Eyanoer PC. Hubungan Indeks Massa Tubuh dengan Waktu Konversi Sputum pada Pasien TB MDR yang Menjalani Pengobatan dengan Panduan Jangka Pendek di RSUP H. Adam Malik Medan. *J Respir Indo*. 2020; 40(40): 225-31.
61. H Fauziah, S Aprianti, I Handayani, NA Kadir. Analysis of Smear Microscopy and Culture Conversion Results in Multidrug-Resistant Tuberculosis Patients with and without Type 2 Diabetes Mellitus. *Indonesian Journal of Clinical Pathology and Medical Laboratory*. 2020; 26(3): 272-6
62. Akinsola OJ, Yusuf OB, Ige OM, Okonji PE. Models for Predicting Time to Sputum Conversion Among Multi-Drug Resistant Tuberculosis Patients in Lagos, South-West Nigeria. *Front Public Health*. 2018; 6: 347-53.

63. Khan S, Choudhary S, Aurangabadkar G, Bankar N. Sputum culture conversion among patients with drug-resistant tuberculosis: A study of various predictors. *J Datta Meghe Inst Med Sci Univ.* 2023; 18:255-62.
64. Meshesha MD. Predictors of sputum culture conversion time among MDR/RR TB patients on treatment in a low-income setting. *PLoS ONE.* 2022; 17(11): e0277642.
65. Ncha R, Variava E, Otworld K, Kawonga M, Martinson NA. Predictors of time to sputum culture conversion in multi-drug-resistant tuberculosis and extensively drug-resistant tuberculosis in patients at Tshepong-Klerksdorp Hospital. *S Afr J Infect Dis.* 2019; 34(1):111-20.
66. Alzarea AI, Saifullah A, Khan YH, Alanazi AS, Alatawi AD, Algarni MA, et al, Evaluation of time to sputum smear conversion and its association with treatment outcomes among drug-resistant tuberculosis patients: a retrospective record-reviewing study. *Front Pharmacol.* 2024; 15:1370344.
67. Gadallah MA, Mokhtar A, Rady M, El-Moghazy E, Fawzy M, Kandil SK. Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt. *J Formos Med Assoc.* 2016;115(11): 997-1003.
68. Brust JCM, Gandhi NR, Wasserman S, Carrara H, Osburn G, Padayatchi N. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000–2003. *Int J Tuberc Lung Dis.* 2021; 25(2): 123–132